UK markets closed
  • NIKKEI 225

    29,106.01
    +505.60 (+1.77%)
     
  • HANG SENG

    26,038.27
    -93.76 (-0.36%)
     
  • CRUDE OIL

    84.67
    +0.91 (+1.09%)
     
  • GOLD FUTURES

    1,795.40
    -11.40 (-0.63%)
     
  • DOW

    35,756.88
    +15.73 (+0.04%)
     
  • BTC-GBP

    45,234.70
    -561.30 (-1.23%)
     
  • CMC Crypto 200

    1,506.79
    +1.64 (+0.11%)
     
  • ^IXIC

    15,235.71
    +9.01 (+0.06%)
     
  • ^FTAS

    4,149.81
    +31.88 (+0.77%)
     

Global Oncology Based In-Vivo CRO Market to Reach $1.5 Billion by 2027

·12-min read

Abstract: - Global Oncology Based In-Vivo CRO Market to Reach $1. 5 Billion by 2027. - Amid the COVID-19 crisis, the global market for Oncology Based In-Vivo CRO estimated at US$957.

New York, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Oncology Based In-Vivo CRO Industry" - https://www.reportlinker.com/p06032380/?utm_source=GNW
4 Million in the year 2020, is projected to reach a revised size of US$1.5 Billion by 2027, growing at a CAGR of 6.6% over the analysis period 2020-2027. Solid Tumors, one of the segments analyzed in the report, is projected to record a 6.5% CAGR and reach US$749.6 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Blood Cancer segment is readjusted to a revised 6.3% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $282.7 Million, While China is Forecast to Grow at 6.2% CAGR
- The Oncology Based In-Vivo CRO market in the U.S. is estimated at US$282.7 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$262.5 Million by the year 2027 trailing a CAGR of 6.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.2% and 5.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.4% CAGR.
- Other Indications Segment to Record 6.9% CAGR
- In the global Other Indications segment, USA, Canada, Japan, China and Europe will drive the 7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$257.1 Million in the year 2020 will reach a projected size of US$411.5 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$172.5 Million by the year 2027.

- Select Competitors (Total 40 Featured) -

  • Champion Oncology, Inc.

  • Charles River Laboratory

  • Covance

  • Crown Bioscience

  • Eurofins Scientific

  • EVOTEC

  • ICON Plc

  • Living Tumor Laboratory

  • MI Bioresearch, Inc.

  • Taconic Biosciences

  • The Jackson Laboratory

  • Wuxi AppTec

  • Xentech




Read the full report: https://www.reportlinker.com/p06032380/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Oncology Based
In-Vivo CRO by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR

Table 2: World Historic Review for Oncology Based In-Vivo CRO
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 3: World 15-Year Perspective for Oncology Based In-Vivo
CRO by Geographic Region - Percentage Breakdown of Value Sales
for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Solid Tumors by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 5: World Historic Review for Solid Tumors by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for Solid Tumors by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Blood Cancer by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 8: World Historic Review for Blood Cancer by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR

Table 9: World 15-Year Perspective for Blood Cancer by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Other Indications
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 11: World Historic Review for Other Indications by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 12: World 15-Year Perspective for Other Indications by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 13: USA Current & Future Analysis for Oncology Based
In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and
Other Indications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 14: USA Historic Review for Oncology Based In-Vivo CRO by
Indication - Solid Tumors, Blood Cancer and Other Indications
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 15: USA 15-Year Perspective for Oncology Based In-Vivo
CRO by Indication - Percentage Breakdown of Value Sales for
Solid Tumors, Blood Cancer and Other Indications for the Years
2012, 2020 & 2027

CANADA
Table 16: Canada Current & Future Analysis for Oncology Based
In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and
Other Indications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 17: Canada Historic Review for Oncology Based In-Vivo CRO
by Indication - Solid Tumors, Blood Cancer and Other
Indications Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR

Table 18: Canada 15-Year Perspective for Oncology Based In-Vivo
CRO by Indication - Percentage Breakdown of Value Sales for
Solid Tumors, Blood Cancer and Other Indications for the Years
2012, 2020 & 2027

JAPAN
Table 19: Japan Current & Future Analysis for Oncology Based
In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and
Other Indications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 20: Japan Historic Review for Oncology Based In-Vivo CRO
by Indication - Solid Tumors, Blood Cancer and Other
Indications Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR

Table 21: Japan 15-Year Perspective for Oncology Based In-Vivo
CRO by Indication - Percentage Breakdown of Value Sales for
Solid Tumors, Blood Cancer and Other Indications for the Years
2012, 2020 & 2027

CHINA
Table 22: China Current & Future Analysis for Oncology Based
In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and
Other Indications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 23: China Historic Review for Oncology Based In-Vivo CRO
by Indication - Solid Tumors, Blood Cancer and Other
Indications Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR

Table 24: China 15-Year Perspective for Oncology Based In-Vivo
CRO by Indication - Percentage Breakdown of Value Sales for
Solid Tumors, Blood Cancer and Other Indications for the Years
2012, 2020 & 2027

EUROPE
Table 25: Europe Current & Future Analysis for Oncology Based
In-Vivo CRO by Geographic Region - France, Germany, Italy, UK
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 26: Europe Historic Review for Oncology Based In-Vivo CRO
by Geographic Region - France, Germany, Italy, UK and Rest of
Europe Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 27: Europe 15-Year Perspective for Oncology Based In-Vivo
CRO by Geographic Region - Percentage Breakdown of Value Sales
for France, Germany, Italy, UK and Rest of Europe Markets for
Years 2012, 2020 & 2027

Table 28: Europe Current & Future Analysis for Oncology Based
In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and
Other Indications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 29: Europe Historic Review for Oncology Based In-Vivo CRO
by Indication - Solid Tumors, Blood Cancer and Other
Indications Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR

Table 30: Europe 15-Year Perspective for Oncology Based In-Vivo
CRO by Indication - Percentage Breakdown of Value Sales for
Solid Tumors, Blood Cancer and Other Indications for the Years
2012, 2020 & 2027

FRANCE
Table 31: France Current & Future Analysis for Oncology Based
In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and
Other Indications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 32: France Historic Review for Oncology Based In-Vivo CRO
by Indication - Solid Tumors, Blood Cancer and Other
Indications Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR

Table 33: France 15-Year Perspective for Oncology Based In-Vivo
CRO by Indication - Percentage Breakdown of Value Sales for
Solid Tumors, Blood Cancer and Other Indications for the Years
2012, 2020 & 2027

GERMANY
Table 34: Germany Current & Future Analysis for Oncology Based
In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and
Other Indications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 35: Germany Historic Review for Oncology Based In-Vivo
CRO by Indication - Solid Tumors, Blood Cancer and Other
Indications Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR

Table 36: Germany 15-Year Perspective for Oncology Based
In-Vivo CRO by Indication - Percentage Breakdown of Value Sales
for Solid Tumors, Blood Cancer and Other Indications for the
Years 2012, 2020 & 2027

ITALY
Table 37: Italy Current & Future Analysis for Oncology Based
In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and
Other Indications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 38: Italy Historic Review for Oncology Based In-Vivo CRO
by Indication - Solid Tumors, Blood Cancer and Other
Indications Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR

Table 39: Italy 15-Year Perspective for Oncology Based In-Vivo
CRO by Indication - Percentage Breakdown of Value Sales for
Solid Tumors, Blood Cancer and Other Indications for the Years
2012, 2020 & 2027

UNITED KINGDOM
Table 40: UK Current & Future Analysis for Oncology Based
In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and
Other Indications - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 41: UK Historic Review for Oncology Based In-Vivo CRO by
Indication - Solid Tumors, Blood Cancer and Other Indications
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 42: UK 15-Year Perspective for Oncology Based In-Vivo CRO
by Indication - Percentage Breakdown of Value Sales for Solid
Tumors, Blood Cancer and Other Indications for the Years 2012,
2020 & 2027

REST OF EUROPE
Table 43: Rest of Europe Current & Future Analysis for Oncology
Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer
and Other Indications - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 44: Rest of Europe Historic Review for Oncology Based
In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and
Other Indications Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 45: Rest of Europe 15-Year Perspective for Oncology Based
In-Vivo CRO by Indication - Percentage Breakdown of Value Sales
for Solid Tumors, Blood Cancer and Other Indications for the
Years 2012, 2020 & 2027

ASIA-PACIFIC
Table 46: Asia-Pacific Current & Future Analysis for Oncology
Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer
and Other Indications - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 47: Asia-Pacific Historic Review for Oncology Based
In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and
Other Indications Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 48: Asia-Pacific 15-Year Perspective for Oncology Based
In-Vivo CRO by Indication - Percentage Breakdown of Value Sales
for Solid Tumors, Blood Cancer and Other Indications for the
Years 2012, 2020 & 2027

REST OF WORLD
Table 49: Rest of World Current & Future Analysis for Oncology
Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer
and Other Indications - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 50: Rest of World Historic Review for Oncology Based
In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and
Other Indications Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 51: Rest of World 15-Year Perspective for Oncology Based
In-Vivo CRO by Indication - Percentage Breakdown of Value Sales
for Solid Tumors, Blood Cancer and Other Indications for the
Years 2012, 2020 & 2027

IV. COMPETITION
Total Companies Profiled: 40
Read the full report: https://www.reportlinker.com/p06032380/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting